Differing effects of denosumab and alendronate on cortical and trabecular bone

Bone

Volumn 59, Issue , 2014, Pages 173-179

  Zebaze, Roger M ^a   Libanati, Cesar ^b   Austin, Matthew ^b   Ghasem Zadeh, Ali ^a   Hanley, David A ^c,h   Zanchetta, Jose R ^d,h   Thomas, Thierry ^e,h   Boutroy, Stephanie ^f,h   Bogado, Cesar E ^d,h   Bilezikian, John P ^g,h   Seeman, Ego ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AMGEN INC   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d Instituto de Investigaciones Metabolicas   (Argentina)

^e UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^f University of Lyon Claude Bernard   (France)

^g College of Physicians and Surgeons Columbia University ^*  (United States)

^h Dept Endocrinology Repatriation Hospital Austin Health The University of Melbourne ^*  (United States)

Author keywords

Alendronate; Bone quality; Denosumab; Intracortical porosity; Structure

Indexed keywords

ALENDRONIC ACID; CALCIUM; DENOSUMAB; PLACEBO; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE REMODELING; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MIDDLE AGED; POROSITY; POSTMENOPAUSE; QUANTITATIVE ANALYSIS; RADIUS; RANDOMIZED CONTROLLED TRIAL; TRABECULAR BONE; TREATMENT DURATION;

ALENDRONATE; BONE QUALITY; DENOSUMAB; INTRACORTICAL POROSITY; STRUCTURE;

AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE AND BONES; CASE-CONTROL STUDIES; COLLAGEN TYPE I; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MIDDLE AGED; PEPTIDES;

EID: 84890155336     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.11.016     Document Type: Article

References (51)

1. Hattner R., Epker B.N., Frost H.M. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature 1965, 206:489-490.
2. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
3. Zebaze R.M., Ghasem-Zadeh A., Bohte A., Iuliano-Burns S., Mirams M., Price R.I., et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 2010, 375:1729-1736.
4. Russell R.G. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006, 1068:367-401.
5. Parfitt A.M., Mathews C.H., Villanueva A.R., Kleerekoper M., Frame B., Rao D.S. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 1983, 72:1396-1409.
6. McKinstry P., Schnitzer J.E., Light T.R., Ogden J.A., Hoffer P. Relationship of 99mTc-MDP uptake to regional osseous circulation in skeletally immature and mature dogs. Skeletal Radiol 1982, 8:115-121.
7. Cook G.J., Lodge M.A., Blake G.M., Marsden P.K., Fogelman I. Differences in skeletal kinetics between vertebral and humeral bone measured by 18F-fluoride positron emission tomography in postmenopausal women. J Bone Miner Res 2000, 15:763-769.
8. Roelofs A.J., Stewart C.A., Sun S., Blazewska K.M., Kashemirov B.A., McKenna C.E., et al. Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo. J Bone Miner Res 2012, 27:835-847.
9. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
10. Lewiecki E.M., Miller P.D., McClung M.R., Cohen S.B., Bolognese M.A., Liu Y., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007, 22:1832-1841.
11. Seeman E., Delmas P.D., Hanley D.A., Sellmeyer D., Cheung A.M., Shane E., et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 2010, 25:1886-1894.
12. Kostenuik P.J., Nguyen H.Q., McCabe J., Warmington K.S., Kurahara C., Sun N., et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009, 24:182-195.
13. Ominsky M.S., Jolette J., Smith S.Y., Vlasseros F., Samadfam R., Kostenuik P.J. Transition from alendronate to denosumab resulted in further reductions in local and systemic bone turnover parameters and reduced cortical porosity in ovariectomized cynomolgus monkeys. J Bone Miner Res 2008, 23:S61.
14. Ohishi M., Chiusaroli R., Ominsky M., Asuncion F., Thomas C., Khatri R., et al. Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. Am J Pathol 2009, 174:2160-2171.
15. Kanis J.A., Borgstrom F., Zethraeus N., Johnell O., Oden A., Jonsson B. Intervention thresholds for osteoporosis in the UK. Bone 2005, 36:22-32.
16. Laib A., Hauselmann H.J., Ruegsegger P. In vivo high resolution 3D-QCT of the human forearm. Technol Health Care 1998, 6:329-337.
17. MacNeil J.A., Boyd S.K. Accuracy of high-resolution peripheral quantitative computed tomography for measurement of bone quality. Med Eng Phys 2007, 29:1096-1105.
18. Zebaze R., Ghasem-Zadeh A., Mbala A., Seeman E. Method and system for image analysis of selected tissue structures Accessed at. http://patentscope.wipo.int/search/en/WO2011029153.
19. Zebaze R., Ghasem-Zadeh A., Mbala A., Seeman E. A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images. Bone 2013, 54:8-20.
20. Bjornerem A., Bui Q.M., Ghasem-Zadeh A., Hopper J.L., Zebaze R., Seeman E. Fracture risk and height: an association partly accounted for by cortical porosity of relatively thinner cortices. J Bone Miner Res 2013, 28:2017-2026.
21. Chiang C.Y., Zebaze R.M., Ghasem-Zadeh A., Iuliano-Burns S., Hardidge A., Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 2013, 52:360-365.
22. Silverman B.W. Density estimation 1986, Chapman and Hall, London.
23. Pinheiro J.C., Bates D.M. Mixed-effects models in S and S-PLUS. Statistics and computing 2000, Springer.
24. The R Development Core Team R: a language and environment for statistical computing Accessed at. http://www.R-project.org.
25. Pinheiro J.C., Bates D.M., DebRoy S., Sarkar D. nlme: linear and nonlinear mixed effects models. R package version 2012, 3:1-104. R Development Core Team.
26. Hoenig J.M., Heisey D.M. The abuse of power: the pervasive fallacy of power calculations in data analysis. Am Stat 2001, 55:19-24.
27. Kostenuik P.J., Smith S.Y., Jolette J., Schroeder J., Pyrah I., Ominsky M.S. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 2011, 49:151-161.
28. Devogelaer J.P., Broll H., Correa-Rotter R., Cumming D.C., De Deuxchaisnes C.N., Geusens P., et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3years in postmenopausal women with osteoporosis. Bone 1996, 18:141-150.
29. Tucci J.R., Tonino R.P., Emkey R.D., Peverly C.A., Kher U., Santora A.C. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996, 101:488-501.
30. Hauge E.M., Qvesel D., Eriksen E.F., Mosekilde L., Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 2001, 16:1575-1582.
31. Modder U.I., Khosla S. Skeletal stem/osteoprogenitor cells: current concepts, alternate hypotheses, and relationship to the bone remodeling compartment. J Cell Biochem 2008, 103:393-400.
32. Eastell R., Christiansen C., Grauer A., Kutilek S., Libanati C., McClung M.R., et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011, 26:530-537.
33. Reid I.R., Miller P.D., Brown J.P., Kendler D.L., Fahrleitner-Pammer A., Valter I., et al. Denosumab phase 3 bone histology Study G. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010, 25:2256-2265.
34. Baron R., Ferrari S., Russell R.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011, 48:677-692.
35. Bone H.G., Bolognese M.A., Yuen C.K., Kendler D.L., Wang H., Liu Y., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008, 93:2149-2157.
36. Genant H.K., Engelke K., Hanley D.A., Brown J.P., Omizo M., Bone H.G., et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010, 47:131-139.
37. Kendler D.L., Roux C., Benhamou C.L., Brown J.P., Lillestol M., Siddhanti S., et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010, 25:72-81.
38. Stolina M., Middleton S., Adamu S., Asuncion F., Geng Z., Ominsky M., et al. The RANKL inhibitor osteoprotegerin (OPG) prevents focal bone erosions in adjuvant arthritic rats without inducing renal pathology: a comparison with zoledronic acid. Ann Rheum Dis 2005, 64:441.
39. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29:155-192.
40. Albright F., Smith P.H., Richardson A.M. Postmenopausal osteoporosis: its clinical features. JAMA 1941, 116:2465-2474.
41. Riggs B.L., Melton L.J. Involutional osteoporosis. N Engl J Med 1986, 314:1676-1686.
42. Schaffler M.B., Burr D.B. Stiffness of compact bone: effects of porosity and density. J Biomech 1988, 21:13-16.
43. Yeni Y.N., Brown C.U., Wang Z., Norman T.L. The influence of bone morphology on fracture toughness of the human femur and tibia. Bone 1997, 21:453-459.
44. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-2026.
45. Mellstrom D.D., Sorensen O.H., Goemaere S., Roux C., Johnson T.D., Chines A.A. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:462-468.
46. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 2000, 11:83-91.
47. Sorensen O.H., Crawford G.M., Mulder H., Hosking D.J., Gennari C., Mellstrom D., et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003, 32:120-126.
48. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 1996, 348:1535-1541.
49. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
50. Nakamura T., Matsumoto T., Sugimoto T., Hosoi T., Miki T., Gorai I., et al. Fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT) 2013, [Submitted for publication].
51. Papapoulos S., Chapurlat R., Libanati C., Brandi M.L., Brown J.P., Czerwinski E., et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012, 27:694-701.